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INTRODUCTION
The Notch pathway is a conserved signaling system used
extensively throughout embryonic development that continues to
function in a cell context-dependent manner in the maintenance of
tissues and stem cells in adults (Artavanis-Tsakonas et al., 1999;
Ehebauer et al., 2006; Weinmaster, 2000). A hallmark of Notch
signaling is the requirement for direct cell-to-cell contact, as both
the Notch ligands and receptors are integral membrane proteins
(D’Souza et al., 2008). Given the widespread use of Notch
signaling, it is not surprising that mutations in receptors and ligands
of the Notch pathway have been implicated in the onset of several
human pathologies, including: cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL), T-cell acute lymphoblastic leukemia (T-ALL) and
Alagille syndrome (AGS) (Gridley, 2007; Hansson et al., 2004;
Hofmann and Iruela-Arispe, 2007b; Weng and Lau, 2005). In
particular, AGS is an autosomal-dominant disorder linked to the
Notch ligand jagged 1 (JAG1) (Alagille et al., 1987; Li et al., 1997;
Oda et al., 1997b) and, to a lesser extent, to the Notch 2 receptor
(McDaniell et al., 2006). The disease is primarily characterized by
paucity of intrahepatic bile ducts (IHBD) in the liver, but also
includes a variety of cardiac, skeletal, renal, vascular and
ophthalmologic abnormalities (Alagille et al., 1987; Li et al., 1997;
Oda et al., 1997a). Although Jag1 mutations produce pleiotropic
effects, the initiating cellular and molecular alterations responsible
for the wide spectrum of AGS phenotypes have not been clearly
defined. Our findings suggest that the initial onset of AGS is
probably rooted during early developmental stages.
The development of IHBDs occurs in a series of sequential steps
that can be molecularly and histologically identified (Lemaigre,
2003; Si-Tayeb et al., 2010). A subpopulation of hepatoblasts
initiates expression of biliary-specific genes, transcription factors
(such as Sox9) and a subset of cytokeratins. This event segregates
the biliary precursor cells (cytokeratin-positive) from cells destined
to become hepatocytes (cytokeratin-negative) (Lemaigre, 2003;
Raynaud et al., 2009). These biliary progenitor cells further
differentiate into (BECs) or cholangiocytes. At later stages in
development (E15.5-E16.5), BECs organize into a single-layered
sheet called the ductal plate, which exclusively surrounds the portal
vein. Biliary morphogenesis proceeds with the sequential and
asymmetrical differentiation of a second ductal plate layer from
hepatoblasts on the parenchymal side to form lumenized mature
bile ducts (Antoniou et al., 2009; Si-Tayeb et al., 2010).
The paucity of bile ducts and histological features of AGS may
occur through several distinct mechanisms: interruption of
cholangiocyte fate, poor proliferation, increased cell death or
defects in terminal differentiation. Although it is clear that JAG1
and NOTCH2 contribute to the disease, it has been difficult to
identify the ligand-expressing cell, the onset and mechanistic origin
of the phenotype, and the specific cellular events that are impaired
in AGS (Lemaigre, 2008; Raynaud et al., 2009).
Upon investigation of the contributions of Jag1 to vascular
smooth muscle in mice, we unexpectedly encountered the major
hepatic phenotype of AGS. Specifically, deletion of Jag1 in
SM22a-expressing cells of the developing portal vein mesenchyme
(PVM) resulted in jaundice, liver failure and paucity of IHBDs.
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SUMMARY
Mutations in the human Notch ligand jagged 1 (JAG1) result in a multi-system disorder called Alagille syndrome (AGS). AGS is
chiefly characterized by a paucity of intrahepatic bile ducts (IHBD), but also includes cardiac, ocular, skeletal, craniofacial and
renal defects. The disease penetration and severity of the affected organs can vary significantly and the molecular basis for this
broad spectrum of pathology is unclear. Here, we report that Jag1 inactivation in the portal vein mesenchyme (PVM), but not in
the endothelium of mice, leads to the hepatic defects associated with AGS. Loss of Jag1 expression in SM22a-positive cells of the
PVM leads to defective bile duct development beyond the initial formation of the ductal plate. Cytokeratin 19-positive cells are
detected surrounding the portal vein, yet they are unable to form biliary tubes, revealing an instructive role of the vasculature in
liver development. These findings uncover the cellular basis for the defining feature of AGS, identify mesenchymal Jag1-
dependent and -independent stages of duct development, and provide mechanistic information for the role of Jag1 in IHBD
formation.
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These findings delineate a crucial role for the vasculature in
providing specific and irreversible instructional information via
Jag1 that is essential for IHBD development.
MATERIALS AND METHODS
Mouse lines
All strains of mice have been previously described: VE-Cadherin-Cre
(Alva et al., 2006), SM22-Cre (TagCre) (Holtwick et al., 2002) and
Jag1lox/lox provided by G. Radtke (Mancini et al., 2005). These mice were
crossed to reporter lines Rosa26R LacZ (Soriano, 1999) or Rosa26R eYFP
(Srinivas et al., 2001), and were backcrossed six generations on a
C57BL/6J background. For assessment of survival of SM22-Cre;Jag1
mice, 108 J1SMKO and 287 J1WT+SMHet mice were sampled. All studies were
conducted in accordance with Animal Research Committee guidelines at
UCLA.
Tissue collection and staining
Standard protocols for collecting, staining, immunohistochemistry, b-
galactosidase (b-Gal) were performed as previously described (Alva et al.,
2006). For non-fluorescent immunostaining, tissues were incubated with
primary antibodies and biotinylated secondary antibodies (Jackson
ImmunoResearch Laboratories), treated with a Vectastain ABC kit (Vector
Labs) and DAB substrate (Vector Labs).
Antibodies, lectins and nuclear imaging
Antibodies for immunohistochemistry included: rabbit wide-spectrum
cytokeratins (Dako) (1:800), rat cytokeratin 8 [Troma I; Developmental
Studies Hybridoma Bank (DHSB)] (1:300), rat cytokeratin 19 (Troma III;
DSHB) (1:300), goat polyclonal jagged 1 (R&D Systems) (1:25); anti-Jag1
(1:200, Santa Cruz Biotechnology) Type IV Collagen (Cosmo Bio)
(1:1000), anti-laminin (Sigma) (1:800), rabbit Sox9 (Chemicon) (1:500),
goat HNF1b (Santa Cruz Biotechnology) (1:25), goat HNF4a (Santa Cruz
Biotechnology) (1:50), rabbit Hes1 (a gift from Ben Stanger, University of
Pennsylvania, Philadelphia, PA, USA) (1:1500), rabbit PECAM1 (a gift
from Joseph Madri, Yale, New Haven, CT, USA) (1:250), Texas-Red-
Phalloidin (Molecular Probes) (1:50) and rat PECAM1 (BD Pharmingen)
(1:250). For Sox9, Hes1, HNF1b and HNF4a immunostaining, tyramide
signal amplification was performed using the TSA Kit (Molecular Probes).
Antibodies used for western blots included cytokeratin 8 (Troma I; DSHB),
cytokeratin 19 (Troma III; DSHB), E-cadherin (Cell Signaling), Notch2
(Santa Cruz Biotechnology; Cell Signaling; R&D Systems) (1:500),
Jagged1 (Santa Cruz Biotechnology) (1:800), a-tubulin, fibronectin and a-
enolase. Fluorescein-labeled Dolichos biflorus agglutinin (DBA) (Vector
Laboratories) was used for FACs. For nuclear counterstaining, we used
DAPI (Invitrogen) (1:1000) and TOPRO-3 (Molecular Probes) (1:500).
Alexa Fluor (Invitrogen) or FITC-conjugated (Jackson ImmunoResearch
Laboratories) fluorescent secondaries were used for confocal evaluation on
a Zeiss LSM multiphoton microscope.
Blood serum analysis
Blood was collected immediately post-mortem from three litters of P25
mice and standard liver panels were performed by the UCLA Department
of Laboratory Animal Medicine.
FACS analysis, cell sorting, western blot analysis and
immunoprecipitation
Livers from E16.5, P0, P2 and P10-11 J1WT, J1SMHet and J1SMKO mice were
processed for FACS analysis, as previously described (Zovein et al., 2010).
DBA was used for BEC identification and negatively gated using APC-
conjugated CD45 antibodies (BD Pharmingen) for neonatal livers. All
samples were stained for viability with 7-AAD (BD Pharmingen) and
analyzed on a FACSCaliber with the appropriate isotype controls. E16.5
and P2 BECs for western blot analysis were counted and protein levels
were quantified. For immunoprecipitation, lysates of embryonic were
quantified for protein concentration (DC protein, BioRad). A total of 800
g per sample was used in a volume of 400 l. Samples were pre-cleared
with beads bound to secondary antibodies and incubated overnight with
anti-Jag1. Recovery of the immunocomplexes and western blot were
carried out as previously described (Chen et al., 2010).
Tissue culture
BECs were collected from J1WT or J1SMKO E16.5 or P0-P2 mice, as already
described, and cells were plated on collagen-coated dishes. For
mesenchyme isolation, whole E16.5 and P0-P2 livers were cut, treated with
0.5 mg/ml collagenase and plated on fibronectin-coated plates. Non-
attached cells were removed 1-2 hours after initial plating by washing the
plates with DMEM. Isolation of PVM was confirmed by eYFP. Dermal
fibroblasts were collected by a similar procedure. For 2D cultures, BECs
and PVM were mixed and cultured on collagen-coated dishes. For 3D
cultures, a matrigel and fibronectin (50 g/ml) gel was mixed gently with
equal number of epithelial and fibroblast/PVM cells. The mixture was
polymerized in 24-well plates for 30 minutes at 37°C and media was
added. Three dimensional cultures were fixed in 1:1 acetone/methanol at
–20°C, washed with 25% sucrose, immunostained and were imaged on a
confocal microscope. For Notch inhibition, cells were treated with 50-100
M DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester), changed every 48 hours. Cultures were grown for 7-14 days
and spheroid formation was assessed. For Notch2 pre-activation, Jag1 was
immobilized on 100 mm2 Petri dishes as previously described (Varnum-
Finney et al., 2000). Briefly, plates were coated with anti-human IgG (Fcg-
specific) at 20 g/ml (Jackson Immuno Research) for 30 minutes, washed
and blocked with 2% BSA for 2 hours. Subsequently, Jag1 (10 g/ml)
(R&D Systems) was bound to the treated plates for 2 hours at 37°C.
Controls included plates treated in an identical manner, but without Jag1.
BECs were plated on Jag1 and Fc-coated plates overnight, removed by
trypsinization and lysed or mixed with PVM for 3D cultures.
RESULTS
Vascular smooth muscle deletion of Jag1
recapitulates the liver phenotype of AGS
To investigate the role of Jag1 within distinct cell populations of
the vasculature, we developed two separate mouse models that
allowed for conditional Jag1 deletion in either vascular smooth
muscle or the endothelium. Jag1 deletion in smooth muscle cells
was investigated in SM22-Cre mice crossed to Jag1 floxed mice
(Fig. 1A) to create Jag1-smooth muscle knockout mice (J1SMKO).
To generate Jag1-endothelial cell knockout mice (J1ECKO), we bred
VE-Cadherin Cre mice with Jag1 floxed mice (Fig. 1A). Both lines
yielded viable pups (Fig. 1B,C), although J1SMKO mice
unexpectedly exhibited a high degree of jaundice and growth
retardation, obvious at birth (Fig. 1B; see Fig. S1 in the
supplementary material). These features were absent in Cre-
negative Jag1 floxed mice (J1WT), Jag1 smooth muscle
heterozygous (J1SMHet) littermates and J1ECKO mice (Fig. 1C). The
J1SMKO mice were born at appropriate Mendelian frequencies;
however, the majority of J1SMKO neonates died within the first 2
days and only a small subset (9/136 total mice) survived beyond 4
weeks (Fig. 1D; Table 1). J1SMKO mice that survived beyond a
week continued to exhibit growth retardation, hair loss and lethargy
that worsened over time (Fig. 1E; see Fig. S1 in the supplementary
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Table 1. Mendelian analysis of mice with smooth muscle Jag1
deletion
Genotype Number of Expected
(at 4 weeks) mice Percentage percentage
Cre– ; J1lox/lox 33 24.3 25
Cre– ; J1lox/+ 49 36.0 25
Cre+ ; J1lox/+ 45 33.1 25
Cre+ ; J1SMKO 9* 6.6 25
Total mice 136
SM22-Cre+;J1lox/+ males were bred with SM22-Cre-;J1lox/lox females. A total of 136
mice were genotyped at 4 weeks of age. Only nine J1SMKO mice (6.6%) survived past
weaning and all demonstrated growth retardation and appeared sickly. 2 test for
J1SMKO mice; P<0.005.
*Mice sick. D
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material). These features recapitulate symptoms displayed by AGS
patients and are clinically related to liver dysfunction (Emerick et
al., 1999; Krantz et al., 1997).
Upon gross examination, the livers of P25 J1SMKO mice
exhibited large patches of bile accumulation within the parenchyma
(Fig. 1F, open arrows) and multiple hemorrhagic foci (Fig. 1F,
chevrons), in contrast to the appearance of J1ECKO and J1WT mice
(Fig. 1F). Histological examination of J1SMKO livers also revealed
bile deposits and areas of necrosis (Fig. 1F, white outlines and open
arrows), hemorrhage, and either absent or incompletely formed bile
ducts near the portal veins (Fig. 1F, arrowhead), when compared to
the ducts (Fig. 1F, arrows) in J1WT and J1ECKO livers. Blood
chemistry profiles of J1SMKO mice additionally revealed increased
serum levels of liver enzymes (Table 2), indicative of extensive
liver dysfunction and a likely cause of the high lethality in the
J1SMKO population.
Identification of BECs using cytokeratin demonstrated that
J1SMKO BECs were unable to organize into tubes (Fig. 1F; see Fig.
S2 in the supplementary material). BECs were, however, located
mostly in a single layer adjacent to the portal vein in J1SMKO mice.
By contrast, J1WT and J1ECKO mice had fully remodeled, lumenized
ducts (Fig. 1F, arrows). The structures in J1SMKO mice resembled
the epithelial sheets of the ductal plate that form during early IHBD
development. Extracellular matrix molecules were expressed at
similar levels between the mice (see Fig. S2 in the supplementary
material).
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Fig. 1. Smooth muscle deletion of Jag1, but not endothelial deletion, leads to jaundice, cholestasis and bile duct paucity. (A)Mating
schema for generating J1SMKO and J1ECKO mice. (B)J1SMKO exhibited jaundice and growth retardation from birth. (C)J1ECKO mice were viable and
normal in size and appearance. (D)Kaplan-meier survival analysis of newborn J1SMKO mice. (E)Weight (mean, in grams) of J1SMKO, J1ECKO and
J1WT+Het mice. Bars indicate s.e.m. (F)(Top) Livers of J1SMKO mice showed hemorrhage (chevrons) and bile deposits (open arrows).
(Middle) Hematoxylin and Eosin staining of P7 livers revealed bile ducts in J1WT and J1ECKO mice (arrows), and a lack of patent bile ducts
(arrowhead), as well as necrosis (broken white line, open arrow), in J1SMKO mice. (Bottom) Cytokeratin immunostaining of P25 livers indicated
bilayered lumenized bile ducts in J1WT and J1ECKO (arrows) and non-lumenized ducts in J1SMKO (open arrows) mice. gb, gall bladder; pv, portal vein.
Scale bars: top row, 20 mm; middle and bottom rows, 100m.
Table 2. Blood chemistry analysis
Alkaline Alanine Aspartate Total Direct Blood
phosphatase amino- amino- bilirubin bilirubin urea -glutamyl Lactate
[13-291] transaminase transaminase [0.1-1.1] conjugated nitrogen Cholesterol transferase dehydrogenase
(U/l) [7-227] (U/l) [37-329] (U/l) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (U/l) (U/l)
J1WT (n3) 354±9.1 91.0±27.6 170±36.9 0.3±0.04 0.3±0.05 17.4±0.8 95.9±2.6 3.0±0.7 374±56.4
J1SMHet (n7) 329±4.7 52.7±8.1 207±68.2 0.3±0.03 0.3±0 19.7±2.3 101.7±10.3 3.0±1.0 478.7±119.8
J1SMKO (n4) 1024±114 227±41.2 368±5.8 3.9±1.6 3.5±1.3 15.0±0.7 246±26.8 7.5±0.6 767±45.7
Serum analysis from P25 J1SMKO mice demonstrated increased liver enzymes, bilirubin (total and direct) and cholesterol levels when compared with a subset of littermate
controls. The laboratory values of J1SMKO mice suggest cholestasis and liver failure, while J1SMHet and J1WT mouse values were within normal limits. The typical range for
mouse serum levels is shown in square brackets. Results are mean±s.e.m. D
E
V
E
LO
P
M
E
N
T
4064
Loss of Jag1 in the periportal mesenchyme affects
completion of bile duct morphogenesis
Although expression of Jag1 in blood vessels is most frequently
confined to arteries (Hofmann and Iruela-Arispe, 2007a; Villa et
al., 2001), the portal vein is an exception to the rule (Fig. 2B)
(Loomes et al., 2007). As a result, much debate has ensued over
whether Jag1 in cells that make up the portal vein (endothelium or
mesenchyme) could be responsible for interacting with Notch2
expressed by BECs to promote bile duct morphogenesis (Geisler et
al., 2008; Kodama et al., 2004; Lemaigre, 2008; Loomes et al.,
2007; Lozier et al., 2008). Using immunocytochemistry during the
stages of IHBD development, Jag1 was found in both the
endothelium of the portal vein and the PVM (Fig. 2A-C, arrows
and asterisks), and in BECs later in duct development (Fig. 2B,C,I-
J). In J1SMKO mice, Jag1 expression was predominantly in the
endothelium and was absent in perivascular mesenchyme (Fig. 2D-
F). Jag1 immunoprecipitation from whole-liver extracts revealed
that loss of Jag1 in J1SMKO livers occurred progressively after
E14.5, during ductal plate morphogenesis (Fig. 2G). We further
isolated endothelium, epithelium and mesenchyme from P3 J1SMKO
and littermate controls (Fig. 2H). All three cell types express Jag1
(Fig. 2H-J), but only loss of Jag1 in the mesenchyme (Fig. 2H,K-
L, Fig. 6A) elicited defects in biliary duct formation and AGS-like
features.
Jag1-positive cells in the PVM (Fig. 2I-J) were adjacent to
BECs during ductal plate formation and morphogenesis.
Furthermore, Jag1 expression in the hepatic artery was also evident
in neonatal J1WT livers (Fig. 2C). Cre-mediated deletion of Jag1
was examined in the endothelium and PVM, and further confirmed
by evaluation of protein expression (Fig. 2D-F,G,H,K-L; see Figs
S2 and S3 in the supplementary material). Jag1 expression in the
BECs of J1SMKO mice was not apparent until P3, which was
slightly delayed compared with Jag1-positive BECs in E18.5 J1WT
mice (Fig. 2I-L; arrowheads). Evaluation of BECs at P3 revealed
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Fig. 2. Loss of Jag1 in portal vein mesenchyme results in defective bile duct morphogenesis. (A-F)During IHBD development, Jag1 was
found in the endothelium (arrows) of both mice, but only in the mesenchyme (asterisks) of J1WT mice. BECs (arrowheads) labeled with wide-
spectrum cytokeratin (ws-CK) form a ductal plate alongside Jag1-positive PVM, while the J1SMKO liver had not yet formed this structure (E). At P3,
the J1WT liver displayed a well-formed bile duct and Jag1 expression (C, arrows) remained in the endothelium, PVM and BECs. J1SMKO mice lack
patent duct formation and showed a single layer of ws-CK positive cells that resembled the primitive ductal plate (pdp) (F, arrowheads).
(G)Immunoprecipitation of Jag1 in whole liver lysates from J1WT and J1SMKO mice at E14.5, E16.5 and E18.5. Ns, non-specific band. (H)Western
blot of isolated endothelium, BECs and PVM from P3 J1WT and J1SMKO livers. (I-L) Jag1 expression (in red) alone in the endothelium and PVM, and
co-localized with ws-CK (green) in BECs (I,J, arrowheads) of E18.5 and P3 J1WT livers. (J,J) Jag1-positive PVM (asterisks) at P3 (J is a higher
magnification of J). (K,K) J1SMKO livers maintain Jag1 expression in the endothelium, but no staining was seen in the PVM or the BECs. (L,L) At
P3, J1SMKO livers showed Jag1 colocalized with ws-CK in the disorganized BECs (arrowheads), but absent from PVM (L is a higher magnification of
L, bracket). bd, bile duct; bec, biliary epithelial cell; dp, ductal plate; en, endothelium; ha, hepatic artery; pdp, primitive ductal plate; pv, portal vein;
pvm, portal vein mesenchyme. Scale bars: 50m.
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that J1SMKO mice retained the non-lumenized structure of the ductal
plate in a stage analogous to E18.5. This occurred despite
expression of Jag1 in BECs (Fig. 2L,L; arrowheads). Loss of Jag1
was evident in the PVM of P3 J1SMKO mice (Fig. 2L; bracket) in
comparison with J1WT mice (Fig. 2J; asterisks).
The unexpected hepatic phenotype of J1SMKO mice prompted us
to examine the temporal and cellular distribution of SM22-Cre in the
context of IHBD development. As IHBD development has been well
characterized (Lemaigre, 2003; Raynaud et al., 2009), we chose
representative time-points encompassing the main stages of
differentiation including: biliary specification (~E12.5-E14.5), ductal
plate formation (~E15.5), ductal plate morphogenesis/lumen
initiation (~E16-birth) and the emergence of differentiated ducts
(birth-P14) (Fig. 3A-D; see Fig. S3 in the supplemental material).
Cre activity, tracked by the Rosa26 reporter mouse line, was found
in vascular elements, including the PVM, and in some endothelium,
a caveat of this Cre line (Zovein et al., 2008) (Fig. 3). Both SM22-
Cre and Jag1 expression during early liver development (E12.5-
E13.5) were mostly confined to the endothelium and some cells in
the liver parenchyma as cytokeratin-positive BECs were emerging
(see Fig. S3 in the supplemental material). Later, during ductal plate
formation and differentiation, BECs were embedded within Cre-
recombined mesenchymal cell populations (Fig. 3B-D). The
developmental window corresponds to the absence of Jag1 within
the PVM in J1SMKO mice (Fig. 2D-F,K-L). Cre protein expression
was evaluated throughout these stages by western blot and was found
as early as E12.5 (Fig. 3E). Cre levels increased at E16.5-E18.5,
during ductal plate morphogenesis (Fig. 3E), but Cre was clearly
absent from BECs (Fig. 3F,F).
We compared Cre recombination within the PVM of J1SMHet,
J1SMKO and J1ECKO neonatal livers and found that J1SMHet and
J1ECKO mice exhibited normal mesenchymal expansion (Fig. 3G,I)
and differentiated bile ducts (arrows). By contrast, J1SMKO PVM
was reduced (Fig. 3H, bracket), and the organization of the BECs
(arrowheads) resembled ductal plate formation at E16.5. Overall,
the findings suggest a lack of progression of biliary duct
morphogenesis beyond the initial formation of the ductal plate.
Additionally, J1SMHet mice showed abnormally organized
cytokeratin-positive cells at 3 months of age (see Fig. S2 in the
supplementary material), similar to the livers of surviving J1SMKO
mice. This may suggest a gene-dose effect of Jag1 protein on
proper bile duct assembly, as previously reported in Jag1
conditional/null mice (Loomes et al., 2007). SM22-Cre;Rosa26R
adult mice (wild-type levels of Jag1 expression) exhibited bile duct
incorporation within the expanded mesenchyme that also
encompasses the vascular smooth muscle population surrounding
the hepatic artery (Fig. 3J) (Lemaigre, 2008).
The PVM probably includes other cell types that may have at
one time expressed SM22a, including hepatic stellate cells
(Suzuki et al., 2008) and myofibroblasts (Libbrecht et al., 2002).
However, the majority of SM22-Cre expression was localized to
mesenchymal tissue, and not BECs or hepatocytes. There was
minimal leakage of b-gal expression into the BEC lineage of
adult SM22-Cre:R26R mice, and Jag1 expression was
maintained in the BECs of J1SMKO mice (Fig. 2L), supporting the
notion that epithelial-expressed Jag1 was not responsible for the
observed biliary defects. Although the SM22-Cre-mediated
deletion might also include a small subset of endothelial cells
within the liver, the levels are minimal (Figs 2, 3). More
importantly, full deletion of Jag1 in the endothelium (Fig. 3I,
open arrows; see Fig. S2 in the supplementary material) does not
recapitulate the hepatic defects of AGS. Instead, our findings
indicate that only the loss of Jag1 in the PVM leads to paucity
of bile ducts.
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Fig. 3. Specificity of Cre expression in
developing livers. (A-D)SM22-Cre;R26R
double transgenic mice were used to trace
Cre activity (b-gal staining, blue) during bile
duct morphogenesis (cytokeratin, black). At
E15.5, BECs (B,B, arrowheads) aggregate
near b-gal-positive mesenchymal cells that
form the primitive ductal plate. By E18.5, a
few lumenized bile ducts (C,C, arrows) form
within the mesenchyme (red bracket) and
continue to develop at P3 (D,D, arrows).
(E)Western blot for Cre on liver lysates from
SM22-Cre;R26R and control mice. Non-
specific bands (arrowhead) indicate loading.
(F)Sequential sections of SM22Cre;Rosa26R
E18.5 (F,F) livers with and without ws-CK
staining. Arrowheads indicate BECs.
(G-I)Mesenchymal layer thickness was
decreased in J1SMKO livers compared with
heterozygous littermates (brackets), and BEC
organization was similar to the primitive
ductal plate (H, arrowhead). In J1ECKO livers,
the endothelium (I, open arrows), but not the
mesenchyme, was b-gal positive. (J)SM22-
Cre;R26R adults show persistence of b-gal
staining in both endothelial and smooth
muscle cells (open arrows), as well as the
PVM (red bracket) surrounding mature bile
ducts (arrows). ha, hepatic artery; pv, portal
vein; Std, molecular weight standard. Scale
bars: 100m in A-D; 50m in A-D,F-J.
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Deletion of Jag1 in the PVM halts BEC
tubulogenesis and disrupts Sox9 expression
Several recently published studies have characterized the
expression of differentiation markers in BECs during the various
stages of bile duct development and morphogenesis, and have
suggested that tubulogenesis occurs through a process of transient
asymmetry (Antoniou et al., 2009; Zong et al., 2009). Thus, we
examined the expression patterns of several BEC markers in
J1SMKO livers to determine whether they were affected by the loss
of Jag1. In particular, Sox9 has been shown to control the timing
of duct maturation, and has been identified as a Notch target gene
(Antoniou et al., 2009; Zong et al., 2009). At E18.5, BECs of
J1WT mice expressed Sox9 contiguously around the portal vein
and in both layers of lumenized ducts (Fig. 4A,C, arrows); by
contrast, J1SMKO mice lacked Sox9 expression (Fig. 4B,D). In
J1WT neonates, Sox9 expression became increasingly confined to
maturing ducts (Fig. 4E,G,I, arrows). In J1SMKO mice, Sox9 was
only found in a few epithelial cells between P1 and P10 (Fig.
4F,H,J, arrows), comparable with expression at E18.5 in wild-
type mice (Fig. 4A,C). These findings support the notion that
Sox9 is a direct target of Jag1-Notch signaling (Antoniou et al.,
2009; Zong et al., 2009).
We also examined the expression of HNF1b and HNF4a, two
genes involved in liver differentiation (Tanimizu and Miyajima,
2004), at E18.5 (see Fig. S4 in the supplemental material). HNF1b,
which plays an essential role in epithelial differentiation (Coffinier
et al., 2002), was expressed in a single layer of ductal cells in
J1SMKO mice, unlike the circumferential expression in the ducts of
J1WT mice. The pattern of expression of HNF4a, a hepatocyte-
specific gene that regulates the development and adhesion of the
epithelium (Battle et al., 2006; Parviz et al., 2003), appeared closer
to the portal vein in J1SMKO livers, probably owing to the loss of
PVM, yet the levels were comparable with wild type (see Fig. S4
in the supplemental material). Similar to homolog of
hairy/enhancer of split-1 (Hes1) knockout mice, J1SMKO mice
appeared to have normal differentiation of BECs from hepatoblasts,
but defective duct morphogenesis (Kodama et al., 2004).
Additionally, the loss of Sox9 has been shown to disturb Hes1
expression (Antoniou et al., 2009). This prompted us to evaluate
Hes1 expression in J1WT and J1SMKO livers (Fig. 4K-R). At E16.5,
Hes1 was present in the single, cytokeratin-positive epithelial layer
of the ductal plate in both mutant and control mice (Fig. 4K-N). By
E18.5, the disorganized BECs of J1SMKO mice maintained Hes1
expression but still in a single layer and lacked the formation of the
second layer noted in the control mice (Fig. 4O-R). Expression
levels also appeared reduced (Fig. 4R).
As the specification and differentiation of BECs are associated
with expression of a cohort of cytokeratins, we examined the
pattern of several markers in the absence of PVM Jag1. Although
the expression level of cytokeratin 8 (CK8), an early BEC marker
(Shiojiri, 1997), was similar between J1WT and J1SMKO mice,
differences in the distribution and cellular organization of this
protein were observed (Fig. 5). At P10, CK8-positive BECs of
wild-type mice were arranged into a lumenized duct within the
PVM (arrows, Fig. 5A,A,E,F), whereas CK8-positive J1SMKO
BECs were disorganized along the portal vein (Fig. 5B,B,F). To
examine whether the number of BECs was affected in the J1SMKO
mice, we used FACS analysis of P0 and P10-P11 livers, and
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Fig. 4. Expression of Sox9
in J1SMKO livers is affected
by the loss of Jag1.
(A-J)Immunostaining
revealed delayed onset and
reduced numbers of Sox9-
positive cells (arrows) in
J1SMKO mice in embryonic and
neonatal livers compared
with J1WT mice. (K-R)Hes1
expression (arrows) at E16.5
(N) was present in both J1WT
and J1SMKO CK19-positive
populations, but was still in
the single layer in the
disorganized BECs of E18.5
J1SMKO livers (R). bd, bile duct;
pv, portal vein.
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compared kinetics of BEC expansion. At P0, the number of BECs
in J1SMKO mice was equivalent to J1WT and J1SMHet littermates, but
the J1SMKO BEC population decreased significantly by P10-P11
(Fig. 5C). The BECs did not appear to progress beyond the
formation of the second layer of the ductal plate, similar to AGS-
associated paucity of bile ducts (Lemaigre, 2008; Li et al., 1997;
Oda et al., 1997b). Furthermore, the differences in numbers of
BECs at P10 indicate that in the absence of PVM-Jag1 these cells
either stop proliferating or undergo apoptosis.
Using sorted BECs from J1WT and J1SMKO mice, we examined the
expression of BEC markers during two stages of IHBD
development: E16.5 and P0. We found increased expression of two
duct-specific cytokeratins, as well as E-cadherin in BECs at P0 (in
both mice) when compared with E16.5 (Fig. 5D). The persistence of
CK19, a marker of later BEC differentiation (Shiojiri, 1997), in
ductal cells has been reported previously in hepatoblast-specific
Notch-deficient mice, but could also be a result of BECs not part of
the developing bile ducts becoming incompetent to receive signals
for elimination (Geisler et al., 2008; Sparks et al., 2009). To closely
examine the cellular distribution of cytokeratins during embryonic
and postnatal stages, we evaluated CK8 in E18.5 and P10 J1WT
livers. At E18.5, CK8 was initially expressed in BECs along the
portal side of the ductal plate, and extended to the cells on the
parenchymal side upon formation of the second layer of the ductal
plate (arrowheads, Fig. 5E). This asymmetric distribution was similar
to that reported for CK19 (Zong et al., 2009) and is indicative of the
establishment of polarity. In addition, keratin filaments were tightly
bundled (open arrows, Fig. 5E) in these columnar cells. By P10,
CK8-positive BECs were cuboidal and incorporated within ducts,
with CK8 ringing the nucleus (arrows, Fig. 5E).
We then compared expression patterns of CK8 and CK19 in
conjunction with a wide-spectrum cytokeratin (ws-CK) antibody
in postnatal J1WT and J1SMKO livers. CK8 and CK19 overlapped
with the ws-CK in J1WT BECs (Fig. 5F,G, arrows) and higher
magnification showed the ring-like distribution of these keratins
in the mature ducts. By contrast, CK8 in the J1SMKO BECs did
not fully overlap with ws-CK expression (Fig. 5F, arrowheads).
Higher magnification revealed disorganized keratin fibers (Fig.
5F, open arrows) and columnar shapes typically seen at E18.5
(Fig. 5E). Similarly, CK19 in J1SMKO mice was expressed along
the portal side, but did not extend to the parenchymal side that
was positive for ws-CK (Fig. 5G, arrowheads). Disorganized
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Fig. 5. Loss of Jag1 halts biliary duct
tubulogenesis. (A-B) Cytokeratin 8 (CK8) in P10
J1WT and J1SMKO livers (higher magnifications in A,B).
CK8-positive BECs formed ducts in J1WT livers (arrows),
while J1SMKO BECs (arrowheads) did not. (C)FACS
analysis of P0 livers from J1WT, J1SMHet and J1SMKO mice
show a decrease number of BECs in J1SMKO mice at
P10-11. Bars represent mean±s.e.m. *P<0.05 (n3-7
animals per time point). (D)Western blot of E16.5 and
P0 sorted BECs from J1WT and J1SMKO livers. E-cadherin
(E-cad), CK8 and cytokeratin 19 (CK19) were
increased in both mice at P0 in relation to E16.5. a-
Enolase was used for loading control. (E)Fluorescent
immunostaining of CK8 (red) and TOPRO3 (blue) in
J1WT livers at E18.5 and P10. CK8 expression was
initially present along the portal side (arrowheads), but
expanded when both epithelial layers were present.
Keratin filaments in BECs were bundled and visible at
E18.5 (open arrows). By P10, BECs were organized
into ducts and CK8 expression circumscribed the cells
(arrows). (F,G)Ws-CK, (green) colocalized with CK8
and CK19 in J1WT P10 livers (arrows, fourth panels). By
contrast, CK8 expression was widespread and did not
fully overlap with ws-CK (F, arrowheads) in J1SMKO
livers. CK19 expression in J1SMKO livers was present (G)
on the portal side of the BEC layer and not on the
parenchymal layer where ws-CK was expressed
(arrowheads). CK8 and CK19 keratin filaments were
less compacted and organized in J1SMKO BECs (open
arrows). pv, portal vein; nt, necrotic tissue. Scale bars:
100m in A,B; 50m in A,B; 50m in E (first and
third panels); 10m in E (second and fourth panels);
50m in F,G; 10m in F,G (fourth panels).
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keratin filaments were also evident (Fig. 5F, open arrow). The
expression pattern of CK19 resembled that of the wild type at an
earlier more immature stage of development (Fig. 4E) (Zong et
al., 2009). Thus, the BECs of J1SMKO mice appear to arrest at an
intermediate stage of IHBD development when cytokeratin
expression is still asymmetrical.
Lack of epithelial aggregation in the absence of
Jag1 from the portal vein mesenchyme
To further clarify the specific contribution of Jag1 in the PVM
during IHBD development, we isolated epithelial and
mesenchymal cells from J1WT and J1SMKO mice at different stages
of duct development and explored their interactions in vitro. BECs
at E16.5, as well as neonatal stages of J1WT and J1SMKO livers were
isolated by FACS (see Fig. S5 in the supplementary material).
BECs from both genotypes grew equally well in culture and PVM
cells were isolated and cultured from dissociated livers of J1WT and
J1SMKO mice (see Fig. S5 in the supplementary material). We
examined the deletion of Jag1 in cultured J1SMKO PVM using
western blots (Fig. 6A), and then employed an in vitro co-culture
system to evaluate the effect of Jag1 loss on BECs. In 2D co-
cultures, BECs and PVM were able to interact; however, in 3D
matrix gels, BECs bound to and grew on PVM cells and eventually
compacted to form spheroids (Fig. 6B, arrowhead). Interestingly,
compaction requires PVM, as co-cultures of BECs with dermal
fibroblasts at the same developmental stage do not induce the
formation of these structures (Fig. 6B). Wild-type E16.5 BECs
were then cultured with either J1WT or J1SMKO PVM to compare
the effects of Jag1 loss. The design of this 3D co-culture system
allowed for the direct use of the Jag1-depleted PVM from J1SMKO
mice at specific stages of duct development. Other ductal culture
systems require the use of Jag1-positive hepatic progenitor lines to
differentiate into the distinct hepatic lineages for ductal
development (Tanimizu et al., 2009).
The formation of cytokeratin-positive spheroids (arrows in Fig. 6C-
F) occurred progressively over several weeks using J1WT PVM. The
spheroids also expressed CK19 in culture (Fig. 6G), and even formed
lumenal structures (see Fig. S5 in the supplementary material). By
contrast, spheroids were rare in J1SMKO PVM/wild-type BEC co-
cultures (Fig. 6C-F). The BECs differentiated and expressed ws-CK
(open arrow, Fig. 6F); however, they were unable to form the
compact spheres shown in J1WT cultures (Fig. 6E,E, arrows). When
J1SMKO BECs were grown on J1WT PVM, spheroids formed,
indicating that Jag1 from the BEC lineage was not sufficiently
instructive for the formation of spheroids (Fig. 6G). Together, these
data suggest that BECs require instructional information from the
PVM, which is specifically mediated by Jag1 in order to initiate
epithelial aggregation and complete duct morphogenesis.
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Fig. 6. Jag1 in the PVM is required for BEC spheroid formation. (A)Western blot of Jag1 in PVM cultures from mutant and control mice.
(B)Two-dimensional co-cultures containing BECs and PVM do not form spheroids, but 3D co-cultures with PVM, not with dermal fibroblasts (DF)
induce clustering of BECs (arrowhead). (C)Wild-type BECs cultured with J1WT PVM form spheroids (arrows), but failed to compact when co-cultured
with J1SMKO PVM. (D)Quantification of spheroids from multiple cultures (n5 independent cultures). *P≤0.001; error bars represent ±s.e.m.
(E-G) Immunostaining of the 3D cultures showed expression of BEC differentiation markers (ws-CK or CK19, in green). Wild-type BECS cultured
with J1SMKO PVM did not form large spheroids, but did show smaller cell aggregates that expressed ws-CK (open arrow), similar to the clumps of
cells around the portal vein seen in vivo (arrows). Scale bars: 100m in B,C,F; 50m in E-G,G; 10m in E,F.
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A narrowly defined window of mesenchymally
derived Jag1 signaling during early liver
development promotes irreversible changes in
BEC differentiation
Using the SM22-Cre line, our data indicated that mesenchymal
Jag1 was not necessary for the initial formation of the ductal
plate nor for the expression of cytokeratins by cholangiocytes,
but nonetheless was required for assembly of mature and patent
bile ducts. Thus, to better define the temporal window of Jag1
signaling during later BEC tubulogenesis, we used
pharmacological blockade of Notch activity (Fig. 7). In the 3D
co-culture system, Notch signaling was blocked using the pan-
Notch inhibitor DAPT in wild-type PVM-epithelial cultures
isolated at E16.5 and P2. Although E16.5 control cultures were
able to form duct-like spheroid structures, exposure to DAPT
effectively blocked compaction of epithelial cells (Fig. 7A)
without affecting viability. By contrast, Notch inhibition did not
affect spheroid formation in P2 BEC cultures (Fig. 7A),
suggesting that P2 cultures have the potential to form spheroids
in the absence of Notch signaling. A possible explanation for
these differences is that an irreversible change in BEC
differentiation (probably driven by Notch activation) had
occurred in P2 epithelial cells that had not yet occurred in E16.5
cells (Fig. 7A). To test this hypothesis, we pre-activated E16.5
wild-type BECs with exogenous Jag1 ligand and then co-
cultured them with J1SMKO PVM (Fig. 7B). Remarkably, the
Jag1-pre-treated BECs enhanced detection of a cleaved form of
Notch2 (Fig. 7B), indicative of Notch2 activation. As previously
shown, E16.5 untreated control BECs did not form spheroids on
J1SMKO PVM. By contrast, Jag1-activated BECs formed these
structures despite being cultured with J1SMKO mesenchyme (Fig.
7B). The findings indicate that the Jag1 signaling axis gives an
instructive cue for spheroid formation during a small, but
critical, time window and is dispensable thereafter. The sum of
these mechanistic experiments identifies both PVM-Jag1-
dependent and -independent events during bile duct
morphogenesis and has further expanded our understanding of
the temporal and spatial involvement of this Notch ligand during
the process of IHBD development (Fig. 8).
DISCUSSION
Absence of Jag1 in the portal vein mesenchyme
results in paucity of bile ducts and reveals the
vascular roots of Alagille syndrome
The data presented in this study provide detailed insight into the
contribution of the Notch ligand Jag1 in the vasculature to liver
morphogenesis and pathology. Our findings indicate that Jag1,
specifically in the PVM, is essential for biliary duct development,
and is required within a critical embryonic timeframe. Initial BEC
specification and the formation of the first layer of ductal plate
appear to be PVM-Jag1 independent using both Cre deletion
models. Importantly, Jag1-dependent signaling in the PVM is
essential for the morphogenesis of BECs, expansion of the
mesenchyme and the organization of mature bile ducts. Loss of
developmental cues initiated by the Jag1-Notch2 signaling axis is
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Fig. 7. Temporal requirement of Jag1 signaling for
morphogenesis of bile ducts. (A)Notch signaling blockade in wild-
type co-cultures of PVM and BECs (at E16.5 and P2) with DAPT
prevents spheroid formation (arrows) at E16.5 but not at P2.
(B)Western blot demonstrates Notch2 activation within BECs after
binding to Jag1 peptide (Fc, control). Black arrow indicates intact
Notch2; black arrowhead indicates cleaved Notch2. When cultured
with J1SMKO PVM, E16.5 BECs previously activated with soluble Jag1
peptide regained the ability to form spheroids (arrows), whereas BECs
treated with Fc control peptide did not. Scale bars: 100m in A,B.
Fig. 8. Spatial and temporal requirement of
Jag1 during IHBD development. BEC
specification and initial ductal plate formation
occurs in a mesenchymal Jag1-independent
manner (steps 1 and 2). Jag1 expression in the
PVM controls the complete formation of the
second layer of the ductal plate, allowing the
BECs to eventually remodel into a lumenized
duct. Expansion of PVM also appears to be
dependent on Jag1 signaling (steps 3 and 4). Loss
of Jag1 expression in the PVM causes duct
development to stall midway during ductal plate
morphogenesis (step 3), leading to a paucity of
bile ducts.
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known to be associated with paucity of bile ducts (one of the most
prominent diagnostic indicators of AGS). The J1SMKO mouse line
described herein provides a new liver-specific AGS model where
conditional deletion of Jag1 in the PVM is sufficient to recapitulate
the hepatic defects of AGS. Although other vascular anomalies
associated with AGS were observed in both the J1SMKO and J1ECKO
mice, further investigation is beyond the scope of the current study.
The connection between how impaired Notch signaling directly
translates to bile duct paucity in AGS has not been fully
mechanistically explained. Although previous work in mice has
uncovered Notch2 requirements for BECs (Geisler et al., 2008;
Tchorz et al., 2009), it remained unknown whether IHBD paucity
is a result of insufficient BEC specification or abnormal ductal
plate morphogenesis. It was also unclear which Jag1-expressing
cell was responsible for the IHBD defects and when Notch
activation by Jag1 was required.
Jag1 expression in the PVM, not the endothelium
or biliary epithelium, directs bile duct
tubulogenesis
A puzzling aspect to AGS is that it encompasses a broad spectrum
of organ variability. Although many reports have subsequently
focused on uncovering the role of Notch2 and other factors
throughout the stages of biliary differentiation, the contribution of
Jag1 has been less clear. Investigations of Jag1 have involved
expression analysis or cell-specific loss-of-function studies that,
despite much effort, have failed to replicate the disease (Crosnier
et al., 2000; Flynn et al., 2004; Jones et al., 2000; Kodama et al.,
2004; Loomes et al., 2007; Loomes et al., 2002; Louis et al., 1999;
Nijjar et al., 2001; Xue et al., 1999). Only Jag1;Notch2 double
heterozygous mice (McCright et al., 2002) and mice with a
missense mutation of Jag1 (Vrijens et al., 2006) were able to
reproduce the major defects of AGS, leaving much controversy
over which Jag1-expressing cell controlled IHBD development.
Full deletion of Jag1 results in death at E10.5 before IHBD
development is initiated, whereas, unlike humans, Jag1
heterozygotes do not exhibit obvious liver defects (Xue et al.,
1999). Ablation of Jag1 in hepatoblasts also did not show evidence
of bile duct paucity (Loomes et al., 2007).
Recently, several groups have reported endothelial-specific Jag1
deletions in mice. However, most animals either died before the
onset of IHBD development or the surviving mice did not display
obvious liver defects (Benedito et al., 2009; High et al., 2008).
Additional data from zebrafish cloche mutants, in which bile ducts
develop normally despite lacking endothelial cells, also support the
idea that endothelial cells are not required for IHBD development
(Lorent et al., 2004). Together with our findings, we suggest that
the endothelium is not responsible for IHBD development. The
PVM had been proposed to be the Jag1-presenting cell population,
but no definitive experiments had been carried out to investigate
this further (Lemaigre, 2008; Si-Tayeb et al., 2010).
Defects in the organization and dilation of the second ductal
layer, as revealed in the J1SMKO mice (Figs 2, 3, 4, and 5), clearly
identifies Jag1 in the PVM as a regulator of biliary morphogenesis
and tubulogenesis. In this regard, we noted a persistence of CK19-
positive cells around the portal vein of surviving J1SMKO mice and
also found that continuous Jag1 signaling is not required for duct
development. Although a Notch inhibitor suppressed spheroid
formation when E16.5 epithelium was used, the same inhibitor did
not prevent neonatal wild-type BECs from organizing spheroids in
vitro on Jag1-null mesenchyme (Fig. 7). It is possible that Jag1
within BECs could be activating Notch2 at the neonatal stage;
however, the levels of Jag1 in E16.5 and P2 epithelium are
equivalent and much lower than those in PVM (see Fig. S5 in the
supplementary material). Thus, it is unlikely that epithelial Jag1 is
playing a role exclusively at the neonatal stage.
The communication required for proper orchestration of duct
morphogenesis, revealed by the heterotypic interactions of the PVM
and BECs, serve to highlight the vascular roots of AGS and to define
the role of Jag1 in bile duct formation (Fig. 8). Although other genes
such as Tgfb and Hes1 have been implicated in IHBD development
with similar biliary defects as the J1SMKO mice, only JAG1 and
NOTCH2 have been linked to AGS (Antoniou et al., 2009; Clotman
et al., 2002). Examination of Hes1 during early stages of IHBD
development (E16.5) in J1SMKO revealed essentially no differences
in expression or distribution compared with wild type, suggesting
that Hes1 is not a target of mesenchymal Jag1. By contrast, during
ductal plate morphogenesis we found that expression of Sox9 was
dependent on the presence of Jag1 in the PVM.
Crosstalk between the portal vein mesenchyme
and biliary epithelium
Our findings support the previously proposed hypothesis for
crossregulation between IHBD morphogenesis and the portal vein
vasculature (Coffinier et al., 2002; Lemaigre, 2003; Libbrecht et
al., 2005; Raynaud et al., 2009). Just as the mesenchyme provides
instructive signals to the developing BECs (Shiojiri and Koike,
1997), the BECs likely exert control over expansion of the PVM,
as well as the development of the hepatic arteries (Lemaigre, 2008;
Raynaud et al., 2009). Two factors important for early BEC
differentiation, HNF1b and HNF6, are expressed in BECs but not
the vasculature; yet, the absence of either leads to vascular defects
(Clotman et al., 2002; Clotman et al., 2003; Coffinier et al., 2002;
Lemaigre, 2003). Hepatic arteries were scarce in J1SMKO livers
(Figs 1, 2; see Fig. S2 in the supplementary material), similar to
HNF1b or HNF6 knockout mice (Clotman et al., 2003; Coffinier
et al., 2002), and the expression of HNF1b itself was delayed in
BECs around the portal vein. The thickness of the PVM layer in
the J1SMKO mice was reduced (Figs 2, 3), whereas reports on Hnf6
knockout mice also note abnormal mesenchyme (Clotman et al.,
2003; Lemaigre, 2003). Thus, BECs may signal back to the PVM
in a heterotypic manner. In the J1SMKO mice, the defect in BEC
tubulogenesis probably prevents this crosstalk from occurring.
The new information included in this study answers several
long-standing questions about the spatial and temporal involvement
of Jag1 in IHBD development and identifies crucial heterotypic
interactions between BECs and blood vessels. In a broader
developmental sense, the insights gleaned from this study
underscore the essential and instructive role of the vasculature in
the organization and differentiation of liver parenchyma. This
instructive contribution has been highlighted in the pancreas and
liver using elegant genetic models that either eliminate or perturb
the endothelium (Cleaver and Melton, 2003; Coultas et al., 2005;
Lammert et al., 2003; Matsumoto et al., 2001; Sakaguchi et al.,
2008). Our studies with a single gene deletion provide further
support for this notion. Collectively, these findings indicate that, in
addition to providing oxygen and nutrients, blood vessels are active
contributors to signaling events that drive organogenesis.
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